SCHEMBL29967937

SCHEMBL29967937

COc1ccc(-c2ccc(Oc3[nH]nnc3C(=O)O)cc2)c(OC)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HAO1 Q9UJM8 6/20 0.41
PRKAG1 P54619 3/20 0.39
PRKAA1 Q13131 3/20 0.39
PRKAB1 Q9Y478 3/20 0.39
BRD9 Q9H8M2 1/20 0.38
BRD7 Q9NPI1 1/20 0.38
ERN1 O75460 2/20 0.38
PDE10A Q9Y233 3/20 0.38
PRKAB2 O43741 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PLAU P00749 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ALPL P05186 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319947 1.00 POLB (0.42) POLBTDP1HAO1PRKAG1PRKAA1
SCHEMBL31166182 0.86 ALPL (0.42) POLBTDP1HAO1PRKAG1PRKAA1
SCHEMBL23319931 0.86 ALPL (0.42) POLBTDP1HAO1PRKAG1PRKAA1
SCHEMBL21296847 0.81 PRKAG1 (0.51) HAO1PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL23319968 0.81 HAO1 (0.50) HAO1PRKAG1PRKAA1PRKAB1ALPL
SCHEMBL29968360 0.81 HAO1 (0.50) HAO1PRKAG1PRKAA1PRKAB1ALPL
SCHEMBL21296956 0.79 HAO1 (0.52) HAO1PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL25463773 0.78 HAO1 (0.38) HAO1PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31166249 0.78 HAO1 (0.44) HAO1PRKAG1PRKAA1PRKAB1ERN1
SCHEMBL23319906 0.78 HAO1 (0.44) HAO1PRKAG1PRKAA1PRKAB1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-11401246-B2 Triazole glycolate oxidase inhibitors Cantero Therapeutics, Inc. (US) 2022-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401246-B2 Triazole glycolate oxidase inhibitors XDH, DUOX1, PNPO POLB 1757/4885TDP1 972/4885HAO1 6/4885
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO POLB 1757/4885TDP1 972/4885HAO1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.